Mycophenolate mofetil monotherapy in the management of paediatric uveitis

Eye

Volumn 25, Issue 4, 2011, Pages 427-435

  Chang, P Y ^a   Giuliari, G P ^a   Shaikh, M ^a   Thakuria, P ^a   Makhoul, D ^a   Foster, C S ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

cellcept; immunomodulatory; immunosuppressive; mycophenolate mofetil; paediatric; uveitis

Indexed keywords

ADALIMUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; IRIDOCYCLITIS; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MOOD; MOUTH ULCER; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PNEUMONIA; PRESCHOOL CHILD; RELAPSE; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 79954476346     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.23     Document Type: Article

References (30)

1. Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-884. (Pubitemid 36765255)
2. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of paediatric uveitis. Ophthalmology 2004; 111: 2299-2306.
3. Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol 2003; 135: 867-878. (Pubitemid 36677406)
4. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Völcker HE. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992; 1: 142-144.
5. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999; 106: 111-118.
6. Kremer JM. Methotrexate and emerging therapies. Clin Exp Rheumatol 1999; 17(6 Suppl 18): S43-S46. (Pubitemid 29503356)
7. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998; 41: 381-391. (Pubitemid 28128761)
8. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365. (Pubitemid 40209138)
9. Heiligenhaus A, Mingels A, Heinz C, Ganser G Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743-748.
10. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P et al. The safety and efficacy of MMF in lupus nephritis: a pilot study Lupus 2001; 10: 606-611. (Pubitemid 32959274)
11. Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
12. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
13. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
14. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents in paediatric renal transplantation: efficacy, side-effects and utilization. Pediatr Transplant 2004; 8: 445-453. (Pubitemid 39279013)
15. Dipchand AI, Benson L, McCrindle BW, Coles J, West L. Mycophenolate mofetil in paediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5: 112-118. (Pubitemid 32298571)
16. Van Mourik ID, Kelly DA. Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001; 3: 43-60. (Pubitemid 32115679)
17. Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003; 18: 445-449. (Pubitemid 36798488)
18. Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK et al. Use of mycophenolate mofetil for chronic refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129: 534-538. (Pubitemid 40769903)
19. Moudgil A, Bagga A, Jordan SC. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol 2005; 20: 1376-1381. (Pubitemid 41403409)
20. Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in paediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1265-1268. (Pubitemid 41222972)
21. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516. (Pubitemid 41224845)
22. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467-471. (Pubitemid 15034518)
23. Thorne JE, Jabs DA, Qazi FA, Nguyen OD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112: 1472-1477. (Pubitemid 41074642)
24. Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788-794. (Pubitemid 44103323)
25. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008; 115: 1416-1421.
26. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003; 110: 1061-1065. (Pubitemid 36560514)
27. Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008; 146: 752-760.
28. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010; 149: 423-432.e1-2.
29. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007; 91: 180-184. (Pubitemid 46202865)
30. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005; 13: 335-351. (Pubitemid 41702757)